Document is current
Any future updates will be listed below
-
Authors
Baxter, Sarah M.
Bjørge, Tone
Bjerkvig, Rolf
Cardwell, Christopher
Engeland, Anders
Eriksson, Julia
Habel, Laurel
Igland, Jannicke
Klungsøyr, Kari
Lunde, Astrid
Miletic, Hrvoje
Olesen, Morten
Pottegård, Anton
Reutfors, Johan
Sharifian, Mohammad Jalil
Linder, Marie
Hicks, Blánaid
-
Funding
Funding for this research was provided by:
Cancer Research UK (PPRCPJT\100017, PPRCPJT\100017, PPRCPJT\100017)
Kreftforeningen (208041-2019, 208041-2019)
- License Information
-
More Information
Article History
Received: 14 January 2025
Accepted: 1 March 2025
First Online: 10 April 2025
Declarations
:
: AP reports participation in research projects funded by Alcon, Almirall, Astellas, Astrazeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all regulator-mandated phase IV-studies, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. ML, JE and JR report participation in research projects funded by Janssen, Swedish Orphan BioVitrum (SOBI), Bayer, Novartis, AbbVie, Novo Nordisk, Pfizer, all with funds paid to the institution where they were employed (no personal fees) and with no relation to the work reported in this paper. JI reports participation in regulator-mandated post-authorisation safety studies (PASS) funded by Sanofi, Pfizer and Novartis, all with funds paid to the institution where she was employed (no personal fees). AL reports participation in PASS funded by Amgen, Sanofi, Pfizer and Novartis, all with funds paid to the institution where she was employed (no personal fees)].
: Approval was obtained for each of the individual datasets from: the Information Governance Review Panel (Wales), the Danish Data Protection Agency, the Regional Committee for Medical and Health Research Ethics (2018/2125/REK vest) (Norway), and the Swedish Ethical Authority, Statistics Sweden and the Swedish National Board of Health and Welfare].
